EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Volume 209 / Numéro 2 (2015) Biologie Aujourd'hui, 209 2 (2015) 145-159 References
Free Access
Issue
Biologie Aujourd'hui
Volume 209, Number 2, 2015
Page(s) 145 - 159
Section Mécanismes de l’immunité anti-virale, défis thérapeutiques et développement de vaccins anti-sida
DOI https://doi.org/10.1051/jbio/2015015
Published online 29 octobre 2015
  • Akira, S., and Hemmi, H. (2003). Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett, 85, 85-95. [CrossRef] [PubMed] [Google Scholar]
  • Bedard, K.M., Wang, M.L., Proll, S.C., Loo, Y.M., Katze, M.G., Gale, M., Jr., and Iadonato, S.P. (2012). Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol, 86, 7334-7344. [CrossRef] [PubMed] [Google Scholar]
  • Cavlar, T., Deimling, T., Ablasser, A., Hopfner, K.P., and Hornung, V. (2013). Species-specific detection of the antiviral small-molecule compound CMA by STING. EMBO J, 32, 1440-1450. [CrossRef] [PubMed] [Google Scholar]
  • Conlon, J., Burdette, D.L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Rathinam, V.A., Monks, B., Jin, T., Xiao, T.S., Vogel, S.N., Vance, R.E., and Fitzgerald, K.A. (2013). Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol, 190, 5216-5225. [CrossRef] [PubMed] [Google Scholar]
  • Dempsey, A., and Bowie, A.G. (2015). Innate immune recognition of DNA: A recent history. Virology, 479-480C, 146-152. [CrossRef] [Google Scholar]
  • Engel, A.L., Holt, G.E., and Lu, H. (2011). The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol, 4, 275-289. [CrossRef] [PubMed] [Google Scholar]
  • Es-Saad, S., Tremblay, N., Baril, M., and Lamarre, D. (2012). Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol, 2, 622-628. [CrossRef] [PubMed] [Google Scholar]
  • Field, A.K., Tytell, A.A., Lampson, G.P., and Hilleman, M.R. (1967). Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA, 58, 1004-1010. [CrossRef] [Google Scholar]
  • Gao, P., Ascano, M., Zillinger, T., Wang, W., Dai, P., Serganov, A.A., Gaffney, B.L., Shuman, S., Jones, R.A., Deng, L., Hartmann, G., Barchet, W., Tuschl, T., and Patel, D.J. (2013). Structure-function analysis of STING activation by c[G(2’,5’)pA(3’,5’)p] and targeting by antiviral DMXAA. Cell, 154, 748-762. [CrossRef] [PubMed] [Google Scholar]
  • Gao, P., Zillinger, T., Wang, W., Ascano, M., Dai, P., Hartmann, G., Tuschl, T., Deng, L., Barchet, W., and Patel, D.J. (2014). Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA. Cell Rep, 8, 1668-1676. [CrossRef] [PubMed] [Google Scholar]
  • Glaz, E.T., Szolgay, E., Stoger, I., and Talas, M. (1973). Antiviral activity and induction of interferon-like substance by quinacrine and acranil. Antimicrob Agents Chemother, 3, 537-541. [CrossRef] [PubMed] [Google Scholar]
  • Gorden, K.B., Gorski, K.S., Gibson, S.J., Kedl, R.M., Kieper, W.C., Qiu, X., Tomai, M.A., Alkan, S.S., and Vasilakos, J.P. (2005). Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol, 174, 1259-1268. [CrossRef] [PubMed] [Google Scholar]
  • Grossberg, S.E. (1977). Nonviral interferon inducers: natural and synthetic products. Tex Rep Biol Med, 35, 111-116. [PubMed] [Google Scholar]
  • Guo, F., Mead, J., Aliya, N., Wang, L., Cuconati, A., Wei, L., Li, K., Block, T.M., Guo, J.T., and Chang, J. (2012). RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response. PLoS One, 7, e42583. [CrossRef] [PubMed] [Google Scholar]
  • Hammerbeck, D.M., Burleson, G.R., Schuller, C.J., Vasilakos, J.P., Tomai, M., Egging, E., Cochran, F.R., Woulfe, S., and Miller, R.L. (2007). Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res, 73, 1-11. [CrossRef] [PubMed] [Google Scholar]
  • Harvey, R., Brown, K., Zhang, Q., Gartland, M., Walton, L., Talarico, C., Lawrence, W., Selleseth, D., Coffield, N., Leary, J., Moniri, K., Singer, S., Strum, J., Gudmundsson, K., Biron, K., Romines, K.R., and Sethna, P. (2009). GSK983: a novel compound with broad-spectrum antiviral activity. Antiviral Res, 82, 1-11. [CrossRef] [PubMed] [Google Scholar]
  • Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., and Akira, S. (2002). Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol, 3, 196-200. [CrossRef] [PubMed] [Google Scholar]
  • Hirota, K., Kazaoka, K., Niimoto, I., Kumihara, H., Sajiki, H., Isobe, Y., Takaku, H., Tobe, M., Ogita, H., Ogino, T., Ichii, S., Kurimoto, A., and Kawakami, H. (2002). Discovery of 8-hydroxyadenines as a novel type of interferon inducer. J Med Chem, 45, 5419-5422. [CrossRef] [PubMed] [Google Scholar]
  • Hoffman, W.W., Korst, J.J., Niblack, J.F., and Cronin, T.H. (1973). N,N-dioctadecyl-N’,N’-bis(2-hydroxyethyl) propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob Agents Chemother, 3, 498-502. [CrossRef] [PubMed] [Google Scholar]
  • Hornung, R.L., Young, H.A., Urba, W.J., and Wiltrout, R.H. (1988). Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta. J Natl Cancer Inst, 80, 1226-1231. [CrossRef] [PubMed] [Google Scholar]
  • Horscroft, N.J., Pryde, D.C., and Bright, H. (2012). Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother, 67, 789-801. [CrossRef] [PubMed] [Google Scholar]
  • Isaacs, A., and Lindenmann, J. (1957). Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci, 147, 258-267. [CrossRef] [PubMed] [Google Scholar]
  • Isaacs, A., Cox, R.A., and Rotem, Z. (1963). Foreign nucleic acids as the stimulus to make interferon. Lancet, 2, 113-116. [CrossRef] [PubMed] [Google Scholar]
  • Isobe, Y., Kurimoto, A., Tobe, M., Hashimoto, K., Nakamura, T., Norimura, K., Ogita, H., and Takaku, H. (2006). Synthesis and biological evaluation of novel 9-substituted-8-hydroxyadenine derivatives as potent interferon inducers. J Med Chem, 49, 2088-2095. [CrossRef] [PubMed] [Google Scholar]
  • Kaufman, H.E., Centifanto, Y.M., Ellison, E.D., and Brown, D.C. (1971). Tilorone hydrochloride: human toxicity and interferon stimulation. Proc Soc Exp Biol Med, 137, 357-360. [CrossRef] [PubMed] [Google Scholar]
  • Kern, E.R., Hamilton, J.R., Overall, J.C., and Glasgow, L.A. (1976). Antiviral activity of BL-3849A, a low-molecular-weight oral interferon inducer. Antimicrob Agents Chemother, 10, 691-696. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Kim, T., Kim, T.Y., Song, Y.H., Min, I.M., Yim, J., and Kim, T.K. (1999). Activation of interferon regulatory factor 3 in response to DNA-damaging agents. J Biol Chem, 274, 30686-30689. [CrossRef] [PubMed] [Google Scholar]
  • Kim, S., Li, L., Maliga, Z., Yin, Q., Wu, H., and Mitchison, T.J. (2013). Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol, 8, 1396-1401. [CrossRef] [PubMed] [Google Scholar]
  • Konishi, H., Okamoto, K., Ohmori, Y., Yoshino, H., Ohmori, H., Ashihara, M., Hirata, Y., Ohta, A., Sakamoto, H., Hada, N., Katsume, A., Kohara, M., Morikawa, K., Tsukuda, T., Shimma, N., Foster, G.R., Alazawi, W., Aoki, Y., Arisawa, M., and Sudoh, M. (2012). An orally available, small-molecule interferon inhibits viral replication. Sci Rep, 2, 259. [CrossRef] [PubMed] [Google Scholar]
  • Kramer, M.J., Cleeland, R., and Grunberg, E. (1976). Antiviral activity of 10-carboxymethyl-9-acridanone. Antimicrob Agents Chemother, 9, 233-238. [CrossRef] [PubMed] [Google Scholar]
  • Kramer, M.J., Taylor, J.L., and Grossberg, S.E. (1981). Induction of interferon in mice by 10-carboxymethyl-9-acridanone. Methods Enzymol, 78, 284-287. [CrossRef] [PubMed] [Google Scholar]
  • Krueger, R.E., and Mayer, G.D. (1970). Tilorone hydrochloride: an orally active antiviral agent. Science, 169, 1213-1214. [CrossRef] [PubMed] [Google Scholar]
  • Lanford, R.E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V.L., Brasky, K.M., Fosdick, A., Frey, C.R., Zheng, J., Wolfgang, G., Halcomb, R.L., and Tumas, D.B. (2013). GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology, 144, 1508-1517, 1517 e1501-1510. [CrossRef] [PubMed] [Google Scholar]
  • Lee, J., Chuang, T.H., Redecke, V., She, L., Pitha, P.M., Carson, D.A., Raz, E., and Cottam, H.B. (2003). Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA, 100, 6646-6651. [CrossRef] [Google Scholar]
  • Lee, J., Wu, C.C., Lee, K.J., Chuang, T.H., Katakura, K., Liu, Y.T., Chan, M., Tawatao, R., Chung, M., Shen, C., Cottam, H.B., Lai, M.M., Raz, E., and Carson, D.A. (2006). Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA, 103, 1828-1833. [CrossRef] [Google Scholar]
  • Li, L., Yin, Q., Kuss, P., Maliga, Z., Millan, J.L., Wu, H., and Mitchison, T.J. (2014). Hydrolysis of 2’3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol, 10, 1043-1048. [CrossRef] [PubMed] [Google Scholar]
  • Lin, C.W., Wu, C.F., Hsiao, N.W., Chang, C.Y., Li, S.W., Wan, L., Lin, Y.J., and Lin, W.Y. (2008). Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents, 32, 355-359. [CrossRef] [PubMed] [Google Scholar]
  • Lucas-Hourani, M., Dauzonne, D., Jorda, P., Cousin, G., Lupan, A., Helynck, O., Caignard, G., Janvier, G., André-Leroux, G., Khiar, S., Escriou, N., Després, P., Jacob, Y., Munier-Lehmann, H., Tangy, F., and Vidalain, P.O. (2013). Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog, 9, e1003678. [CrossRef] [PubMed] [Google Scholar]
  • Martinez-Gil, L., Ayllon, J., Ortigoza, M.B., Garcia-Sastre, A., Shaw, M.L., and Palese, P. (2012). Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS One, 7, e49049. [CrossRef] [PubMed] [Google Scholar]
  • Mayer, G.D., and Krueger, R.F. (1970). Tilorone hydrochloride: mode of action. Science, 169, 1214-1215. [CrossRef] [PubMed] [Google Scholar]
  • Meyer, T., Surber, C., French, L.E., and Stockfleth, E. (2013). Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs, 22, 149-159. [CrossRef] [PubMed] [Google Scholar]
  • Miller, R.L., Gerster, J.F., Owens, M.L., Slade, H.B., and Tomai, M.A. (1999). Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol, 21, 1-14. [CrossRef] [PubMed] [Google Scholar]
  • Pan, Q., de Ruiter, P.E., Metselaar, H.J., Kwekkeboom, J., de Jonge, J., Tilanus, H.W., Janssen, H.L., and van der Laan, L.J. (2012). Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology, 55, 1673-1683. [CrossRef] [PubMed] [Google Scholar]
  • Patel, D.A., Patel, A.C., Nolan, W.C., Zhang, Y., and Holtzman, M.J. (2012). High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One, 7, e36594. [CrossRef] [PubMed] [Google Scholar]
  • Pestka, S. (2007). Purification and cloning of interferon alpha. Curr Top Microbiol Immunol, 316, 23-37. [PubMed] [Google Scholar]
  • Prantner, D., Perkins, D.J., Lai, W., Williams, M.S., Sharma, S., Fitzgerald, K.A., and Vogel, S.N. (2012). 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem, 287, 39776-39788. [CrossRef] [PubMed] [Google Scholar]
  • Pryde, D.C., Tran, T.D., Jones, P., Parsons, G.C., Bish, G., Adam, F.M., Smith, M.C., Middleton, D.S., Smith, N.N., Calo, F., Hay, D., Paradowski, M., Proctor, K.J.W., Parkinson, T., Laxton, C., Fox, D.N.A., Horscroft, N.J., Ciaramella, G., Jones, H.M., Duckworth, J., Benson, N., Harrison, A., and Webster, R. (2011). The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection. Med Chem Comm, 2, 185-189. [CrossRef] [Google Scholar]
  • Raj, N.B., and Pitha, P.M. (1993). 65-kDa protein binds to destabilizing sequences in the IFN-beta mRNA coding and 3’ UTR. FASEB J, 7, 702-710. [PubMed] [Google Scholar]
  • Sariol, C.A., Martinez, M.I., Rivera, F., Rodriguez, I.V., Pantoja, P., Abel, K., Arana, T., Giavedoni, L., Hodara, V., White, L.J., Anglero, Y.I., Montaner, L.J., and Kraiselburd, E.N. (2011). Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques. PLoS One, 6, e19323. [CrossRef] [PubMed] [Google Scholar]
  • Schlee, M., Barchet, W., Hornung, V., and Hartmann, G. (2007). Beyond double-stranded RNA-type I IFN induction by 3pRNA and other viral nucleic acids. Curr Top Microbiol Immunol, 316, 207-230. [PubMed] [Google Scholar]
  • Schmid, S., Mordstein, M., Kochs, G., Garcia-Sastre, A., and Tenoever, B.R. (2010). Transcription factor redundancy ensures induction of the antiviral state. J Biol Chem, 285, 42013-42022. [CrossRef] [PubMed] [Google Scholar]
  • Schoggins, J.W., and Rice, C.M. (2011). Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol, 1, 519-525. [CrossRef] [PubMed] [Google Scholar]
  • Silin, D.S., Lyubomska, O.V., Ershov, F.I., Frolov, V.M., and Kutsyna, G.A. (2009). Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharm Des, 15, 1238-1247. [CrossRef] [PubMed] [Google Scholar]
  • Siminoff, P., Bernard, A.M., Hursky, V.S., and Price, K.E. (1973). BL-20803, a new, low-molecular-weight interferon inducer. Antimicrob Agents Chemother, 3, 742-743. [CrossRef] [PubMed] [Google Scholar]
  • Stevenson, N.J., Murphy, A.G., Bourke, N.M., Keogh, C.A., Hegarty, J.E., and O’Farrelly, C. (2011). Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One, 6, e27866. [CrossRef] [PubMed] [Google Scholar]
  • Stringfellow, D.A., Vanderberg, H.C., and Weed, S.D. (1980). Interferon induction by 5-halo-6-phenyl pyrimidinones. J Interferon Res, 1, 1-14. [CrossRef] [PubMed] [Google Scholar]
  • Stringfellow, D.A., Weed, S.D., and Underwood, G.E. (1979). Antiviral and interferon-inducing properties of 1,5-diamino anthraquinones. Antimicrob Agents Chemother, 15, 111-118. [CrossRef] [PubMed] [Google Scholar]
  • Tai, Z.F., Zhang, G.L., and Wang, F. (2012). Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen. Biol Pharm Bull, 35, 65-71. [CrossRef] [PubMed] [Google Scholar]
  • Tanji, H., Ohto, U., Shibata, T., Miyake, K., and Shimizu, T. (2013). Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science, 339, 1426-1429. [CrossRef] [PubMed] [Google Scholar]
  • Taylor, J.L., Schoenherr, C., and Grossberg, S.E. (1980a) Protection against Japanese encephalitis virus in mice and hamsters by treatment with carboxymethylacridanone, a potent interferon inducer. J Infect Dis, 142, 394-399. [CrossRef] [PubMed] [Google Scholar]
  • Taylor, J.L., Schoenherr, C.K., and Grossberg, S.E. (1980b) High-yield interferon induction by 10-carboxymethyl-9-acridanone in mice and hamsters. Antimicrob Agents Chemother, 18, 20-26. [CrossRef] [PubMed] [Google Scholar]
  • Thomas, E., Feld, J.J., Li, Q., Hu, Z., Fried, M.W., and Liang, T.J. (2011) Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology, 53, 32-41. [CrossRef] [PubMed] [Google Scholar]
  • Tijono, S.M., Guo, K., Henare, K., Palmer, B.D., Wang, L.C., Albelda, S.M., and Ching, L.M. (2013) Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br J Cancer, 108, 1306-1315. [CrossRef] [PubMed] [Google Scholar]
  • Vilcek, J. (2007) Interferon research BC (before cloning). Curr Top Microbiol Immunol, 316, 9-22. [PubMed] [Google Scholar]
  • Wheelock, E.F. (1965) Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science, 149, 310-311. [CrossRef] [Google Scholar]
  • Wong, J.P., Christopher, M.E., Viswanathan, S., Karpoff, N., Dai, X., Das, D., Sun, L.Q., Wang, M., and Salazar, A.M. (2009). Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine, 27, 3481-3483. [CrossRef] [PubMed] [Google Scholar]
  • Wu, C.C., Li, Y.C., Wang, Y.R., Li, T.K., and Chan, N.L. (2013). On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Res, 41, 10630-10640. [CrossRef] [PubMed] [Google Scholar]
  • Yan, D., Krumm, S.A., Sun, A., Steinhauer, D.A., Luo, M., Moore, M.L., and Plemper, R.K. (2013). Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response. J Virol, 87, 11076-11087. [CrossRef] [PubMed] [Google Scholar]
  • Yeo, K.L., Chen, Y.L., Xu, H.Y., Dong, H., Wang, Q.Y., Yokokawa, F., and Shi, P.Y. (2015). Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob Agents Chemother, 59, 2086-2093. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Zhao, J., Wohlford-Lenane, C., Zhao, J., Fleming, E., Lane, T.E., McCray, P.B., Jr., and Perlman, S. (2012). Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. J Virol, 86, 11416-11424. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.